Asthma drug repurposed in fight against ovarian cancer
NCT ID NCT04339140
Summary
This study tested whether zafirlukast, a medication approved for asthma, could help control early signs of ovarian cancer returning. It involved a small group of patients whose cancer had relapsed based only on a blood marker (CA-125), not on scans. The goal was to see if the drug could lower this marker and potentially delay the need for stronger treatments like chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.